Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Business Segments — Amortization expense

Similar metrics at other companies

National Health Investors logo
NHISHOP — Amortization expense
$1.5M+900%
NewtekOne, Inc. logo
NEWTBanking — Amortization expense
$36K-12.2%
NewtekOne, Inc. logo
NEWTNSBF — Amortization expense
$0
NewtekOne, Inc. logo
NEWTPayments — Amortization expense
$0
Cboe Global Markets logo
CBOEOptions — Amortization expense
$1.5M-11.8%
GTL
GTLSSpecialty Products — Amortization expense
$4.4M-12.0%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of sales (excluding intangible amortization)23,66317,52745,78334,651
General and administrative expenses (excluding stock-based compensation)17,37813,09036,55324,771
Commercialization and Medical Affairs expenses (excluding stock-based compensation)48,20439,59092,42275,372
Research and development expenses (excluding stock-based compensation)76,30138,443150,02274,258
Acquired IPR&D16,435742,7375,000
Stock-based compensation30,11418,23087,24033,702
Intangible amortization6,6855,89413,37011,788
Loss from operations$(42,537)$(4,989)$(832,002)$(20,172)

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s business segments — amortization expense?
Mirum Pharmaceuticals, Inc. (MIRM) reported business segments — amortization expense of $6.69M in Q2 2026.
What does business segments — amortization expense mean?
Represents the systematic allocation of the cost of intangible assets, such as patents or acquired licenses, over their useful lives. This non-cash expense reflects the consumption of the economic value of the company's intellectual property portfolio.

Ask your AI about Mirum Pharmaceuticals, Inc.'s business segments — amortization expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude